Showing results (431-440 of 531) with videos related to

Sort By:
Pageof 54
Molecular Cancer Research : MCR|March 14, 2019
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma CellsSeung-Cheol Lee, Alexander A Shestov, Lili Guo, et al.
Blood Advances|December 10, 2024
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysisPeter A Riedell, Connor B Grady, Loretta J Nastoupil, et al.
The Lancet. Oncology|July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
American Journal of Hematology|August 19, 2007
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl, Stephen V Liu, Elise A Chong, et al.
Transplantation and Cellular Therapy|March 17, 2024
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell LymphomaElise A Chong, Emeline R Chong, Dylan Therwhanger, et al.
American Journal of Hematology|February 19, 2015
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemiaAnthony R Mato, Kenneth A Foon, Tatyana Feldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaMarco Ruella, Saad S Kenderian, Olga Shestova, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Blood and Lymphatic Cancer : Targets and Therapy|September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial TherapyChaitra Ujjani, Anthony Mato, Brian T Hill, et al.
Pageof 54